Toyota|$17.68 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.76 (¥4,281)+1.93%▲ (in JPY terms)
SoftBank|$23.37 (¥3,738)-3.04%▼ (in JPY terms)
MUFG|$21.87 (¥3,498)-0.11%▼ (in JPY terms)
Keyence|$469.07 (¥75,030)-0.91%▼ (in JPY terms)
Nintendo|$53.53 (¥8,563)+2.29%▲ (in JPY terms)
NTT|$1.05 (¥168)+3.27%▲ (in JPY terms)
Takeda|$42.67 (¥6,825)+2.28%▲ (in JPY terms)
Tokyo Electron|$58.17 (¥9,304)+0.35%▲ (in JPY terms)
Recruit|$104.50 (¥16,715)-5.59%▼ (in JPY terms)
ITOCHU|$15.08 (¥2,413)+1.60%▲ (in JPY terms)
Honda|$11.33 (¥1,812)+2.40%▲ (in JPY terms)
Shin-Etsu|$36.20 (¥5,791)+1.44%▲ (in JPY terms)
Tokio Marine|$3.71 (¥594)+0.32%▲ (in JPY terms)
Fast Retailing|$501.33 (¥80,190)-0.36%▼ (in JPY terms)
Toyota|$17.68 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.76 (¥4,281)+1.93%▲ (in JPY terms)
SoftBank|$23.37 (¥3,738)-3.04%▼ (in JPY terms)
MUFG|$21.87 (¥3,498)-0.11%▼ (in JPY terms)
Keyence|$469.07 (¥75,030)-0.91%▼ (in JPY terms)
Nintendo|$53.53 (¥8,563)+2.29%▲ (in JPY terms)
NTT|$1.05 (¥168)+3.27%▲ (in JPY terms)
Takeda|$42.67 (¥6,825)+2.28%▲ (in JPY terms)
Tokyo Electron|$58.17 (¥9,304)+0.35%▲ (in JPY terms)
Recruit|$104.50 (¥16,715)-5.59%▼ (in JPY terms)
ITOCHU|$15.08 (¥2,413)+1.60%▲ (in JPY terms)
Honda|$11.33 (¥1,812)+2.40%▲ (in JPY terms)
Shin-Etsu|$36.20 (¥5,791)+1.44%▲ (in JPY terms)
Tokio Marine|$3.71 (¥594)+0.32%▲ (in JPY terms)
Fast Retailing|$501.33 (¥80,190)-0.36%▼ (in JPY terms)

admin

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be installed in Iwata City, Shizuoka Prefecture, and a demonstration experiment will begin in April. Collaboration with the city will be carried out to verify its use in the event of a disaster.”

by

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be in … 続きを読む

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in cisplatin-eligible muscle-invasive bladder cancer were presented at the 2026 American Society of Clinical Oncology (ASCO GU) Annual Meeting.”

by

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate … 続きを読む

Sister site: Lagrange Financial News (Japanese-language)
Contact